Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HOTAIRM1-HOXA-AS2 readthrough transcript is a long non-coding RNA resulting from read-through transcription between two lncRNAs, HOTAIRM1 and HOXA-AS2, within the human HOXA gene cluster. While its components (HOTAIRM1 and HOXA-AS2) have individually documented roles in regulation of chromatin structure, gene expression, cell differentiation, and apoptosis (particularly in hematologic contexts), the specific biological role of the readthrough transcript itself has not been characterized or linked to therapeutic targeting or clinical biomarker use[1][3]. Readthrough transcripts are primarily noted in genomic databases and may reflect cellular transcriptional complexity rather than distinct biological entities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HOTAIRM1-HOXA-AS2 readthrough transcript (HOTAIRM1-HOXA-AS2).